Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2014, Article ID 572491, 10 pages
http://dx.doi.org/10.1155/2014/572491
Review Article

Isoprostanes and Neuroprostanes as Biomarkers of Oxidative Stress in Neurodegenerative Diseases

1Department of Physical Medicine, Medical University of Lodz, Hallera 1, Lodz, Poland
2Neurorehabilitation Ward, III General Hospital in Lodz, Milionowa 14, Lodz, Poland
3Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland
4Department of Physiology and Pharmacology “Vittorio Erspamer”, Sapienza University of Rome, Rome, Italy
5Department of Toxicology, Faculty of Pharmacy with Division of Medical Analytics, Wroclaw Medical University, Borowska 211, 50-556 Wroclaw, Poland

Received 12 February 2014; Revised 28 March 2014; Accepted 31 March 2014; Published 29 April 2014

Academic Editor: Kota V. Ramana

Copyright © 2014 Elżbieta Miller et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. M. Enciu, M. Gherghiceanu, and B. O. Popescu, “Triggers and effectors of oxidative stress at blood-brain barrier level: relevance for brain ageing and neurodegeneration,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 297512, 12 pages, 2013. View at Publisher · View at Google Scholar
  2. E. Niki, “Lipid peroxidation products as oxidative stress biomarkers,” BioFactors, vol. 34, no. 2, pp. 171–180, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Santos, C. R. Almodovar, A. L. Bulteau, and C. M. Gomes, “Neurodegeneration, neurogenesis, and oxidative stress,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 730581, 2 pages, 2013. View at Publisher · View at Google Scholar
  4. G. Cappellano, M. Carecchio, T. Fleetwood et al., “Immunity and inflammation in neurodegenerative diseases,” American Journal of Neurodegenerative Disease, vol. 2, no. 2, pp. 89–107, 2013. View at Google Scholar
  5. G. Almer, P. Teismann, Z. Stevic et al., “Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients,” Neurology, vol. 58, no. 8, pp. 1277–1279, 2002. View at Google Scholar · View at Scopus
  6. T. Farooqui and A. A. Farooqui, “Lipid-mediated oxidative stress and inflammation in the pathogenesis of Parkinson's disease,” Parkinson's Disease, vol. 2011, Article ID 247467, 9 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Guest, R. Grant, T. A. Mori, and K. D. Croft, “Changes in oxidative damage, inflammation and [NAD(H)] with age in cerebrospinal fluid,” PLoS ONE, vol. 9, no. 1, Article ID e85335, 2014. View at Publisher · View at Google Scholar
  8. L. J. Roberts II and G. L. Milne, “Isoprostanes,” Journal of Lipid Research, vol. 50, pp. S219–S223, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Mattsson, S. Haghighi, O. Andersen et al., “Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients,” Neuroscience Letters, vol. 414, no. 3, pp. 233–236, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Minghetti, A. Greco, F. Cardone et al., “Increased brain synthesis of prostaglandin E2 and F2-isoprostane in human and experimental transmissible spongiform encephalopathies,” Journal of Neuropathology and Experimental Neurology, vol. 59, no. 10, pp. 866–871, 2000. View at Google Scholar · View at Scopus
  11. T. J. Montine, J. F. Quinn, D. Milatovic et al., “Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease,” Annals of Neurology, vol. 52, no. 2, pp. 175–179, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Yao, V. Zhukareva, S. Sung et al., “Enhanced brain levels of 8,12-iso-iPF2α-VI differentiate AD from frontotemporal dementia,” Neurology, vol. 61, no. 4, pp. 475–478, 2003. View at Google Scholar · View at Scopus
  13. D. Praticò, V. M. Y. Lee, J. Q. Trojanowski, J. Rokach, and G. A. Fitzgerald, “Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo,” FASEB Journal, vol. 12, no. 15, pp. 1777–1783, 1998. View at Google Scholar · View at Scopus
  14. S. E. Browne and M. F. Beal, “Oxidative damage in Huntington's disease pathogenesis,” Antioxidants and Redox Signaling, vol. 8, no. 11-12, pp. 2061–2073, 2006. View at Google Scholar · View at Scopus
  15. S. Kralovicova, S. N. Fontaine, A. Alderton et al., “The effects of prion protein expression on metal metabolism,” Molecular and Cellular Neuroscience, vol. 41, no. 2, pp. 135–147, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. B. S. Wong, T. Pan, T. Liu et al., “Prion disease: a loss of antioxidant function?” Biochemical and Biophysical Research Communications, vol. 275, no. 2, pp. 249–252, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Minghetti, F. Cardone, A. Greco et al., “Increased CSF levels of prostaglandin E2 in variant Creutzfeldt-Jakob disease,” Neurology, vol. 58, no. 1, pp. 127–129, 2002. View at Google Scholar · View at Scopus
  18. S. Arlt, A. Kontush, I. Zerr et al., “Increased lipid peroxidation in cerebrospinal fluid and plasma from patients with creutzfeldt-jakob disease,” Neurobiology of Disease, vol. 10, no. 2, pp. 150–156, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Mitsumoto, R. Santella, X. Liu et al., “Oxidative stress biomarkers in sporadic ALS,” Amyotrophic Lateral Sclerosis, vol. 9, no. 3, pp. 177–183, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Zhang, Q. Zhang, J. Niu et al., “Screening of microRNAs associated with Alzheimer's disease using oxidative stress cell model and different strains of senescence accelerated mice,” Journal of the Neurological Sciences, vol. 338, pp. 57–64, 2014. View at Google Scholar
  21. K. D. Jacob, N. Noren, N. Hooten, A. R. Trzeciak, and M. K. Evans, “Markers of oxidant stress that are clinically relevant in aging and age-related disease,” Mech Ageing, vol. 134, pp. 139–157, 2013. View at Google Scholar
  22. A. A. Farooqui, L. A. Horrocks, and T. Farooqui, “Interactions between neural membrane glycerophospholipid and sphingolipid mediators: a recipe for neural cell survival or suicide,” Journal of Neuroscience Research, vol. 85, no. 9, pp. 1834–1850, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. R. E. Gonsette, “Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity,” Journal of the Neurological Sciences, vol. 274, no. 1-2, pp. 48–53, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Halliwell and C. Y. J. Lee, “Using isoprostanes as biomarkers of oxidative stress: some rarely considered issues,” Antioxidants and Redox Signaling, vol. 13, no. 2, pp. 145–156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Barrera, “Oxidative stress and lipid peroxidation products in cancer progression and therapy,” ISRN Oncology, vol. 2012, Article ID 137289, 21 pages, 2012. View at Publisher · View at Google Scholar
  26. Y. Dotan, D. Lichtenberg, and I. Pinchuk, “Lipid peroxidation cannot be used as a universal criterion of oxidative stress,” Progress in Lipid Research, vol. 43, no. 3, pp. 200–227, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. G. L. Milne, H. Yin, K. D. Hardy, S. S. Davies, and L. J. Roberts, “Isoprostane generation and function,” Chemical Reviews, vol. 111, no. 10, pp. 5973–5996, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. L. J. Roberts II and J. D. Morrow, “Products of the isoprostane pathway: unique bioactive compounds and markers of lipid peroxidation,” Cellular and Molecular Life Sciences, vol. 59, no. 5, pp. 808–820, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. K. D. Hardy, B. E. Cox, G. L. Milne, H. Yin, and L. J. Roberts II, “Nonenzymatic free radical-catalyzed generation of 15-deoxy-Δ12,14 J2-like compounds (deoxy-J2-isoprostanes) in vivo1,” Journal of Lipid Research, vol. 52, no. 1, pp. 113–124, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. R. C. Murphy and E. Fahy, “Isoprostane nomenclature: more suggestions,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 82, no. 2-3, pp. 69–70, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. S. G. Harris, J. Padilla, L. Koumas, D. Ray, and R. P. Phipps, “Prostaglandins as modulators of immunity,” Trends in Immunology, vol. 23, no. 3, pp. 144–150, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. E. E. Reich, W. R. Markesbery, L. J. Roberts II, L. L. Swift, J. D. Morrow, and T. J. Montine, “Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease,” American Journal of Pathology, vol. 158, no. 1, pp. 293–297, 2001. View at Google Scholar · View at Scopus
  33. E. L. Streck, G. A. Czapski, and C. Gonçalves da Silva, “Neurodegeneration, mitochondrial dysfunction, and oxidative stress,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 826046, 2 pages, 2013. View at Publisher · View at Google Scholar
  34. Y. Chen, J. D. Morrow, and L. J. Roberts II, “Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway,” Journal of Biological Chemistry, vol. 274, no. 16, pp. 10863–10868, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Chen, W. E. Zackert, L. J. Roberts II, and J. D. Morrow, “Evidence for the formation of a novel cyclopentenone isoprostane, 15-A(2t)-isoprostane (8-iso-prostaglandin A2) in vivo,” Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol. 1436, no. 3, pp. 550–556, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. R. D. O’Brien, “Fats and oils analysis,” in Fats and Oils: Formulating and Processing for Applications, pp. 197–260, CRC Press, Boca Raton, Fla, USA, 3rd edition, 2009. View at Google Scholar
  37. C. de Felice, C. Signorini, T. Durand et al., “F2-dihomo-isoprostanes as potential early biomarkers of lipid oxidative damage in Rett syndrome,” Journal of Lipid Research, vol. 52, no. 12, pp. 2287–2297, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. A. E. Barden, T. B. Corcoran, E. Mas et al., “Is there a role for isofurans and neuroprostanes in pre-eclampsia and normal pregnancy?” Antioxidants and Redox Signaling, vol. 16, no. 2, pp. 165–169, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. J. D. Brooks, G. L. Milne, H. Yin, S. C. Sanchez, N. A. Porter, and J. D. Morrow, “Formation of highly reactive cyclopentenone isoprostane compounds (A 3/J3-isoprostanes) in vivo from eicosapentaenoic acid,” Journal of Biological Chemistry, vol. 283, no. 18, pp. 12043–12055, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Comporti, C. Signorini, B. Arezzini, D. Vecchio, B. Monaco, and C. Gardi, “F2-isoprostanes are not just markers of oxidative stress,” Free Radical Biology and Medicine, vol. 44, no. 3, pp. 247–256, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Zaja-Milatovic, R. C. Gupta, M. Aschner, and D. Milatovic, “Protection of DFP-induced oxidative damage and neurodegeneration by antioxidants and NMDA receptor antagonist,” Toxicology and Applied Pharmacology, vol. 240, no. 2, pp. 124–131, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Milatovic, T. J. Montine, and M. Aschner, “Measurement of isoprostanes as markers of oxidative stress,” Methods in Molecular Biology, vol. 758, pp. 195–204, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. E. D. 'Amico, P. Factor-Litvak, R. M. Santella, and H. Mitsumoto, “Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis,” Free Radical Biology & Medicine, vol. 65, pp. 509–527, 2013. View at Publisher · View at Google Scholar
  44. J. Wong-Ekkabut, Z. Xu, W. Triampo, I. M. Tang, D. P. Tieleman, and L. Monticelli, “Effect of lipid peroxidation on the properties of lipid bilayers: a molecular dynamics study,” Biophysical Journal, vol. 93, no. 12, pp. 4225–4236, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Yehuda, S. Rabinovitz, R. L. Carasso, and D. I. Mostofsky, “The role of polyunsaturated fatty acids in restoring the aging neuronal membrane,” Neurobiology of Aging, vol. 23, no. 5, pp. 843–853, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. T. J. Montine, M. D. Neely, J. F. Quinn et al., “Lipid peroxidation in aging brain and Alzheimer's disease,” Free Radical Biology and Medicine, vol. 33, no. 5, pp. 620–626, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. E. Miller, A. Walczak, J. Saluk, M. B. Ponczek, and I. Majsterek, “Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis,” Clinical Biochemistry, vol. 45, no. 1-2, pp. 26–30, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. Z. Korade, L. Xu, K. Mirnics, and N. A. Porter, “Lipid biomarkers of oxidative stress in a genetic mouse model of Smith-Lemli-Opitz syndrome,” Journal of Inherited Metabolic Disease, vol. 36, no. 1, pp. 113–122, 2013. View at Publisher · View at Google Scholar
  49. G. L. Milne, B. Gao, E. S. Terry, W. E. Zackert, and S. C. Sanchez, “Measurement of F2-isoprostanes and isofurans using gas chromatography-mass spectrometry,” Free Radical Biology & Medicine, vol. 59, pp. 36–44, 2013. View at Publisher · View at Google Scholar
  50. B. Casetta, M. Longini, F. Proietti, S. Perrone, and G. Buonocore, “Development of a fast and simple LC-MS/MS method for measuring the F2-isoprostanes in newborns,” Journal of Maternal-Fetal and Neonatal Medicine, vol. 25, no. 1, pp. 114–118, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. G. L. Milne, H. Yin, and J. D. Morrow, “Human biochemistry of the isoprostane pathway,” Journal of Biological Chemistry, vol. 283, no. 23, pp. 15533–15537, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. G. L. Milne, H. Yin, K. D. Hardy, S. S. Davies, and L. J. Roberts, “Isoprostane generation and function,” Chemical Reviews, vol. 111, no. 10, pp. 5973–5996, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Bleich, S. Kropp, D. Degner et al., “Creutzfeldt-Jakob disease and oxidative stress,” Acta Neurologica Scandinavica, vol. 101, no. 5, pp. 332–334, 2000. View at Publisher · View at Google Scholar · View at Scopus
  54. T. J. Montine, M. F. Beal, D. Robertson et al., “Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease,” Neurology, vol. 52, no. 5, pp. 1104–1105, 1999. View at Google Scholar · View at Scopus
  55. E. Miller, M. Mrowicka, J. Saluk-Juszczak, and M. Ireneusz, “The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis,” Neurochemical Research, vol. 36, no. 6, pp. 1012–1016, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. L. Minghetti, F. Cardone, A. Greco et al., “Increased CSF levels of prostaglandin E2 in variant Creutzfeldt-Jakob disease,” Neurology, vol. 58, no. 1, pp. 127–129, 2002. View at Google Scholar · View at Scopus
  57. D. T. Walsh, V. H. Perry, and L. Minghetti, “Cyclooxygenase-2 is highly expressed in microglial-like cells in a murine model of prion disease,” Glia, vol. 29, pp. 392–396, 2000. View at Google Scholar
  58. C. Consilvio, A. M. Vincent, and E. L. Feldman, “Neuroinflammation, COX-2, and ALS—a dual role?” Experimental Neurology, vol. 187, no. 1, pp. 1–10, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. L. J. Roberts II, J. P. Fessel, and S. S. Davies, “The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation,” Brain Pathology, vol. 15, no. 2, pp. 143–148, 2005. View at Google Scholar · View at Scopus
  60. D. Milatovic and M. Aschner, “Measurement of isoprostanes as markers of oxidative stress in neuronal tissue,” in Current Protocols in Toxicology, unit 12.14, pp. 1–12, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Melo, L. Monteiro, R. M. F. Lima, D. M. de Oliveira, M. D. de Cerqueira, and R. S. El-Bachá, “Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives,” Oxidative Medicine and Cellular Longevity, vol. 2011, Article ID 467180, 14 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. G. G. Ortiz, F. P. Pacheco-Moisés, O. K. Bitzer-Quintero et al., “Immunology and oxidative stress in multiple sclerosis: clinical and basic approach,” Journal of Cerebral Blood Flow & Metabolism, vol. 34, pp. 34–42, 2014. View at Publisher · View at Google Scholar
  63. R. Sultana and D. A. Butterfield, “Role of oxidative stress in the progression of Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 19, no. 1, pp. 341–353, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Ayala-Peña, “Role of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesis,” Free Radical Biology & Medicine, vol. 62, pp. 102–110, 2013. View at Publisher · View at Google Scholar
  65. D. A. Butterfield, M. L. Bader Lange, and R. Sultana, “Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease,” Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol. 1801, no. 8, pp. 924–929, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Greco, L. Minghetti, and G. Levi, “Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases,” Neurochemical Research, vol. 25, no. 9-10, pp. 1357–1364, 2000. View at Google Scholar · View at Scopus
  67. E. Miller, “Neurodegenerative diseases,” Advances in Experimental Medicine and Biology, vol. 724, pp. 228–238, 2012. View at Google Scholar
  68. D. Karussis, “The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review,” Journal of Autoimmunity, vol. 48-49, pp. 134–142, 2014. View at Publisher · View at Google Scholar
  69. S. Gandhi and A. Y. Abramov, “Mechanism of oxidative stress in neurodegeneration,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 428010, 11 pages, 2012. View at Publisher · View at Google Scholar
  70. L. K. Peterson and R. S. Fujinami, “Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis,” Journal of Neuroimmunology, vol. 184, no. 1-2, pp. 37–44, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. E. Miller, M. Mrowicka, K. Malinowska, J. Mrowicki, J. Saluk-Juszczak, and J. Kȩdziora, “Effects of whole-body cryotherapy on a total antioxidative status and activities of antioxidative enzymes in blood of depressive multiple sclerosis patients,” World Journal of Biological Psychiatry, vol. 12, no. 3, pp. 223–227, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Ljubisavljevic, I. Stojanovic, D. Pavlovic et al., “Suppression of the lipid peroxidation process in the CNS reduces neurological expression of experimentally induced autoimmune encephalomyelitis,” Folia Neuropathologica, vol. 51, pp. 51–57, 2013. View at Google Scholar
  73. A. Greco and L. Minghetti, “Isoprostanes as biomarkers and mediators of oxidative injury in infant and adult central nervous system diseases,” Current Neurovascular Research, vol. 1, no. 4, pp. 341–354, 2004. View at Google Scholar · View at Scopus
  74. S. Mondragón-Rodríguez, G. Perry, X. Zhu, and J. Boehm, “Amyloid beta and tau proteins as therapeutic targets for Alzheimer's disease treatment: rethinking the current strategy,” International Journal of Alzheimer's Disease, vol. 2012, Article ID 630182, 7 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. M. G. Savelieff, S. Lee, Y. Liu, and M. H. Lim, “Untangling amyloid-β, tau, and metals in Alzheimer's disease,” ACS Chemical Biology, vol. 8, pp. 856–865, 2013. View at Publisher · View at Google Scholar
  76. G. Ellis, E. Fang, M. Maheshwari et al., “Lipid oxidation and modification of amyloid-β (Aβ) in vitro and in vivo,” Journal of Alzheimer's Disease, vol. 22, no. 2, pp. 593–607, 2010. View at Google Scholar · View at Scopus
  77. R. Sultana, M. Perluigi, and A. D. Butterfield, “Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain,” Free Radical Biology & Medicine, vol. 62, pp. 157–169, 2013. View at Publisher · View at Google Scholar
  78. S. M. Pritchard, P. J. Dolan, A. Vitkus, and G. V. W. Johnson, “The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics,” Journal of Cellular and Molecular Medicine, vol. 15, no. 8, pp. 1621–1635, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. Y. Zhao and B. Zhao, “Oxidative stress and the pathogenesis of Alzheimer's disease,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 316523, 10 pages, 2013. View at Publisher · View at Google Scholar
  80. E. S. Musiek, J. K. Cha, H. Yin et al., “Quantification of F-ring isoprostane-like compounds (F4-neuroprostanes) derived from docosahexaenoic acid in vivo in humans by a stable isotope dilution mass spectrometric assay,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 799, no. 1, pp. 95–102, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. J. Long, P. He, Y. Shen, and R. Li, “New evidence of mitochondria dysfunction in the female Alzheimer's disease brain: deficiency of estrogen receptor-β,” Journal of Alzheimer's Disease, vol. 30, pp. 545–558, 2012. View at Google Scholar
  82. A. Mancini, S. Raimondo, M. Persano et al., “Estrogens as antioxidant modulators in human fertility,” International Journal of Endocrinology, vol. 2013, Article ID 607939, 6 pages, 2013. View at Publisher · View at Google Scholar
  83. D. Praticò, J. Rokach, and R. K. Tangirala, “Brains of aged apolipoprotein E-deficient mice have increased levels of F2-isoprostanes, in vivo markers of lipid peroxidation,” Journal of Neurochemistry, vol. 73, no. 2, pp. 736–741, 1999. View at Publisher · View at Google Scholar · View at Scopus
  84. F. Sánchez-López, I. Tasset, E. Agüera et al., “Oxidative stress and inflammation biomarkers in the blood of patients with Huntington's disease,” Neurological Research, vol. 34, pp. 721–724, 2012. View at Publisher · View at Google Scholar
  85. M. A. Sorolla, G. Reverter-Branchat, J. Tamarit, I. Ferrer, J. Ros, and E. Cabiscol, “Proteomic and oxidative stress analysis in human brain samples of Huntington disease,” Free Radical Biology and Medicine, vol. 45, no. 5, pp. 667–678, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. S. E. Browne and M. F. Beal, “Oxidative damage in Huntington's disease pathogenesis,” Antioxidants and Redox Signaling, vol. 8, no. 11-12, pp. 2061–2073, 2006. View at Google Scholar · View at Scopus
  87. F. Haun, T. Nakamura, and S. A. Lipton, “Dysfunctional mitochondrial dynamics in the pathophysiology of neurodegenerative diseases,” Journal of Cell Death, vol. 6, pp. 27–35, 2013. View at Google Scholar
  88. E. C. Stack, W. R. Matson, and R. J. Ferrante, “Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants,” Annals of the New York Academy of Sciences, vol. 1147, pp. 79–92, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. L. Gan and J. A. Johnson, “Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseases,” Biochimica et Biophysica Acta, 2013. View at Publisher · View at Google Scholar
  90. A. Carrizzo, A. Di Pardo, V. Maglione et al., “Nitric oxide dysregulation in platelets from patients with advanced huntington disease,” PLoS ONE, vol. 9, no. 2, Article ID e89745, 2014. View at Publisher · View at Google Scholar
  91. N. Stoy, G. M. Mackay, C. M. Forrest et al., “Tryptophan metabolism and oxidative stress in patients with Huntington's disease,” Journal of Neurochemistry, vol. 93, no. 3, pp. 611–623, 2005. View at Publisher · View at Google Scholar · View at Scopus
  92. N. Klepac, M. Relja, R. Klepac, S. Hećimović, T. Babić, and V. Trkulja, “Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects: a cross-sectional study,” Journal of Neurology, vol. 254, no. 12, pp. 1676–1683, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. B. S. Wong, T. Liu, R. Li et al., “Increased levels of oxidative stress markers detected in the brains of mice devoid of prion protein,” Journal of Neurochemistry, vol. 76, no. 2, pp. 565–572, 2001. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Guentchev, T. Voigtländer, C. Haberler, M. H. Groschup, and H. Budka, “Evidence for oxidative stress in experimental prion disease,” Neurobiology of Disease, vol. 7, no. 4, pp. 270–273, 2000. View at Publisher · View at Google Scholar · View at Scopus
  95. B. S. Wong, D. R. Brown, T. Pan et al., “Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities,” Journal of Neurochemistry, vol. 79, no. 3, pp. 689–698, 2001. View at Publisher · View at Google Scholar · View at Scopus
  96. C. Bate, S. Rutherford, M. Gravenor, S. Reid, and A. Williams, “Cyclo-oxygenase inhibitors protect against prion-induced neurotoxicity in vitro,” NeuroReport, vol. 13, no. 15, pp. 1933–1938, 2002. View at Google Scholar · View at Scopus
  97. S. Boillée, C. Vande Velde, and D. Cleveland, “ALS: a disease of motor neurons and their nonneuronal neighbors,” Neuron, vol. 52, no. 1, pp. 39–59, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. P. F. Pradat, S. Attarian, J. P. Camdessanché et al., “Research in amyotrophic lateral sclerosis: what is new in 2009?” Revue Neurologique, vol. 166, no. 8-9, pp. 683–698, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. H. Mitsumoto, R. Santella, X. Liu et al., “Oxidative stress biomarkers in sporadic ALS,” Amyotrophic Lateral Sclerosis, vol. 9, no. 3, pp. 177–183, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. S. C. Barber and P. J. Shaw, “Oxidative stress in ALS: key role in motor neuron injury and therapeutic target,” Free Radical Biology and Medicine, vol. 48, no. 5, pp. 629–641, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. G. Almer, C. Guegan, P. Teismann et al., “Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis,” Annals of Neurology, vol. 49, no. 2, pp. 176–185, 2001. View at Google Scholar